（文章来源：证券日报） 证券日报网讯 1月13日，博雅生物在互动平台回答投资者提问时表示，公司2026年1月9日含信用账户合 并名册的股东人数为30763户。 ...

Group 1 - The core viewpoint of the news is that Boya Bio's stock performance and financing activities indicate a mixed outlook, with significant financing activity but a decline in net profit year-over-year [1][2]. - On January 9, Boya Bio's stock rose by 0.82%, with a trading volume of 110 million yuan. The financing buy-in amount was 17.34 million yuan, while the financing repayment was 35.24 million yuan, resulting in a net financing outflow of 17.89 million yuan [1]. - As of January 9, the total balance of margin trading for Boya Bio was 685 million yuan, with a financing balance of 683 million yuan, accounting for 5.76% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of December 31, Boya Bio had 30,100 shareholders, a slight decrease of 0.03% from the previous period, while the average circulating shares per person increased by 0.03% to 16,737 shares [2]. - For the period from January to September 2025, Boya Bio reported a revenue of 1.474 billion yuan, representing a year-over-year growth of 18.38%. However, the net profit attributable to the parent company was 343 million yuan, reflecting a year-over-year decrease of 16.90% [2]. - Boya Bio has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 489 million yuan distributed over the past three years [3].

证券日报网讯1月8日，博雅生物（300294）在互动平台回答投资者提问时表示，公司始终关注行业发展 趋势，并聚焦有利于提升公司核心竞争力、创造长期价值的战略机会。目前无应披露而未披露的信息， 请投资者以公司公告为准。 ...

证券日报网讯1月6日，博雅生物（300294）在互动平台回答投资者提问时表示，公司经理层的薪酬由基 本年薪、年度绩效奖金、任期激励、津贴补贴和福利等组成，其中年度绩效奖金、任期激励为浮动薪 酬。薪酬水平已参考行业、实际经营情况等因素。关于公司经理层的薪酬机制及薪酬结构等请参阅《公 司经理层成员薪酬管理办法》。 ...

Market Performance - The biopharmaceutical sector increased by 0.55% on January 6, with Liaoning Chengda leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Liaoning Chengda (600739) closed at 12.27, with a rise of 7.16% and a trading volume of 530,500 shares, amounting to a transaction value of 633 million yuan [1] - Dongbao Biological (300239) closed at 6.18, up by 5.64%, with a trading volume of 454,500 shares and a transaction value of 278 million yuan [1] - Olin Biological (616889) closed at 27.66, increasing by 3.83%, with a trading volume of 74,400 shares and a transaction value of 204 million yuan [1] - Kanghong Pharmaceutical (002773) closed at 33.75, up by 2.37%, with a trading volume of 249,700 shares and a transaction value of 838 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 323 million yuan [2] - The net inflow from speculative funds was 104 million yuan [2] Detailed Capital Flow for Selected Stocks - Liaoning Chengda had a net inflow of 34.37 million yuan from institutional investors, while it faced a net outflow of 18.32 million yuan from retail investors [3] - Dongbao Biological saw a net inflow of 21.29 million yuan from institutional investors, with a net outflow of 13.16 million yuan from retail investors [3] - Tian Tan Biological (600161) had a net inflow of 18.06 million yuan from institutional investors, with a net outflow of 10.02 million yuan from retail investors [3]

Group 1 - The core point of the article is that Boya Bio (300294) reported the number of shareholders as of December 31, 2025, which is 30,126 accounts [1]

Core Viewpoint - Boya Bio (300294) has announced its participation in the establishment of the second phase of the China Resources Pharmaceutical Industry Investment Fund, contributing 60 million RMB to a total fund size of 1 billion RMB [1] Group 1: Stock Performance - As of January 5, 2026, Boya Bio's stock closed at 22.97 RMB, up 1.64% from the previous trading day [1] - The stock opened at 22.59 RMB, reached a high of 23.01 RMB, and a low of 22.59 RMB, with a trading volume of 97.67 million RMB and a turnover rate of 0.85% [1] Group 2: Fund Establishment - The board of directors and supervisory board of China Resources Boya Bio Pharmaceutical Group approved the investment in the second phase of the fund on July 17, 2025 [1] - The fund has been registered with the Asset Management Association of China, with a registration code of SBLL28, managed by Shenzhen China Resources Capital Equity Investment Co., Ltd., and custodied by China Merchants Bank [1] - The registration was completed on December 30, 2025, and the first phase of capital contribution has been fulfilled [1]

进展暨完成基金备案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、对外投资概述 为落实华润博雅生物制药集团股份有限公司（以下简称公司）发展战略，有 效控制创新项目前期风险，储备优质战略项目资源，提升公司中长期持续发展与 盈利能力，公司于 2025 年 7 月 17 日召开第八届董事会第十四次会议、第八届监 事会第十一次会议，审议通过了《关于参与设立华润医药产业投资基金二期暨关 联交易的议案》。公司以自有资金认缴出资 6,000 万元人民币参与投资设立华润 （成都）医药产业股权投资基金合伙企业（有限合伙），基金规模为 10 亿元人 民币。 具体内容，详见公司分别于 2025 年 7 月 18 日和 2025 年 10 月 28 日在巨潮 资讯网（网址：http://www.cninfo.com.cn）上披露的《公司关于参与设立华润医 药产业投资基金二期暨关联交易的公告》（公告编号：2025-052)、《公司关于 参与设立华润医药产业投资基金二期暨关联交易的进展公告》（公告编号： 2025-079)。 二、本次对外投资进展情况 近日，华润（成都）医药产业股权 ...

证券日报网讯 12月24日，博雅生物在互动平台回答投资者提问时表示，公司2025年12月19日含信用账 户合并名册的股东人数为30136户。 （文章来源：证券日报） ...

证券日报网讯12月17日，博雅生物（300294）在互动平台回答投资者提问时表示，截至目前，公司暂无 变更股票简称计划。 ...